© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Eton Pharmaceuticals, Inc. (ETON) stock surged +2.53%, trading at $35.70 on NASDAQ, up from the previous close of $34.82. The stock opened at $34.93, fluctuating between $34.65 and $35.99 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 26, 2026 | 34.93 | 35.99 | 34.65 | 35.70 | 1M |
| Jun 25, 2026 | 33.98 | 35.54 | 33.93 | 34.82 | 412.96K |
| Jun 24, 2026 | 34.40 | 34.89 | 32.93 | 33.98 | 446.01K |
| Jun 23, 2026 | 32.34 | 34.00 | 31.88 | 33.49 | 572.01K |
| Jun 22, 2026 | 32.91 | 33.48 | 31.95 | 32.72 | 223.52K |
| Jun 18, 2026 | 33.31 | 33.31 | 31.43 | 32.48 | 607.18K |
| Jun 17, 2026 | 32.45 | 33.25 | 32.03 | 32.76 | 341.84K |
| Jun 16, 2026 | 32.28 | 32.78 | 31.77 | 32.35 | 186.41K |
| Jun 15, 2026 | 31.79 | 32.18 | 30.89 | 32.15 | 263.24K |
| Jun 12, 2026 | 32.12 | 32.78 | 31.27 | 31.59 | 205.76K |
| Jun 11, 2026 | 30.96 | 32.69 | 29.06 | 32.11 | 260.49K |
| Jun 10, 2026 | 30.70 | 31.68 | 30.27 | 30.95 | 265.56K |
| Jun 09, 2026 | 30.32 | 31.11 | 29.91 | 30.53 | 219.05K |
| Jun 08, 2026 | 29.43 | 30.06 | 28.79 | 29.95 | 498.97K |
| Jun 05, 2026 | 29.03 | 29.76 | 28.41 | 29.13 | 236.57K |
| Jun 04, 2026 | 27.61 | 29.10 | 27.57 | 28.90 | 719.51K |
| Jun 03, 2026 | 27.20 | 27.64 | 26.66 | 27.61 | 325.22K |
| Jun 01, 2026 | 30.34 | 30.54 | 28.48 | 28.68 | 383.72K |
| May 29, 2026 | 31.62 | 31.96 | 30.08 | 30.45 | 376.41K |
| May 28, 2026 | 32.13 | 32.78 | 31.58 | 31.86 | 390.9K |
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| Employees | 44 |
| Beta | 0.89 |
| Sales or Revenue | $21.25M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |